Dear Dr. Roach: About six years ago, I was diagnosed with prostate cancer. I chose to have a high-intensity focused ultrasound (HIFU), which ultimately wasn’t successful. I was told that surgery after ...
Dear Dr. Roach: About six years ago, I was diagnosed with prostate cancer. I chose to have a high-intensity focused ultrasound (HIFU), which ultimately wasn't successful. I was told that surgery after ...
DEAR DR. ROACH: About six years ago, I was diagnosed with prostate cancer. I chose to have a high-intensity focused ultrasound (HIFU), which ultimately wasn’t successful. I was told that surgery after ...
Dear Dr. Roach: About six years ago, I was diagnosed with prostate cancer. I chose to have a high-intensity focused ultrasound (HIFU), which ultimately wasn’t successful. I was told that surgery after ...
8.9% of patients on combo had little to no cancer at surgery vs 1% on hormone therapy alone Treatment regimen cut disease recurrence or death risk by 20% Researchers call data 'paradigm changing' J&J ...
With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...
A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...
A virus has stopped pancreatic cancer in its tracks in three people in a clinical trial in the US. Further evaluation is needed in larger trials, but the early results are encouraging, especially ...
Less is more in the case of this cancer treatment. The most common form of cancer among men in the US, after skin cancer, prostate cancer often comes with traditional treatments that cause difficult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results